A. Rephaeli

发表

Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice.

B. Pace, K. Peterson, A. Nudelman, 2019, Blood cells, molecules & diseases.

ALA Induced Heme Synthesis: Fine Tuning Mechanisms of PBG Deaminase and ALA Dehydratase

A. Nudelman, A. Rephaeli, M. Zvi, 2014 .

A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.

Z. Malik, A. Nudelman, A. Rephaeli, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications

A. Nudelman, A. Rephaeli, R. Zhuk, 2000 .

Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs.

J. Rishpon, Lilach Bareket, A. Nudelman, 2010, Bioelectrochemistry.

The effect of membrane potential on the mammalian sodium‐potassium pump reconstituted into phospholipid vesicles.

A. Rephaeli, W. Stein, S. Karlish, 1987, The Journal of physiology.

Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells

A. Nudelman, A. Rephaeli, L. Maron, 2005, Journal of Cancer Research and Clinical Oncology.

The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity

A. Nudelman, S. Cutts, A. Rephaeli, 2008, Cancer Chemotherapy and Pharmacology.

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity

A. Nudelman, S. Cutts, A. Rephaeli, 2007, British Journal of Cancer.

Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells

S. Sukumar, A. Nudelman, S. Cutts, 2003, Cancer biology & therapy.

The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

A. Nudelman, S. Cutts, A. Rephaeli, 2006, Investigational New Drugs.

A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.

W. Miller, S. Waxman, A. Nudelman, 2003, Molecular cancer research : MCR.

Effects of crp mutations on adenosine 3',5'-monophosphate metabolism in Salmonella typhimurium

M. Saier, A. Rephaeli, 1976, Journal of bacteriology.

Cardioprotection by AN-7 a prodrug of the histone deacetylase inhibitor butyric acid: Selective activity in hypoxic cardiomyocytes and cardiofibroblasts.

M. Zahalka, A. Nudelman, A. Rephaeli, 2020, European journal of pharmacology.

Modulating ALA-PDT efficacy of mutlidrug resistant MCF-7 breast cancer cells using ALA prodrug.

Z. Malik, A. Nudelman, A. Rephaeli, 2011, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury.

A. Nudelman, A. Rephaeli, H. Schlesinger, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner.

Z. Malik, A. Nudelman, A. Rephaeli, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor

A. Nudelman, S. Cutts, A. Rephaeli, 2012, PloS one.

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.

M. Diccianni, A. Batova, A. Yu, 2002, Blood.

The Histone Deacetylase Inhibitor AN-9 has Selective Toxicity to Acute Leukemia and Drug-Resistant Primary Leukemia and Cancer Cell Lines Toxicity of AN-9

A. Batova, A. Rephaeli, 2002 .

Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)

A. Nudelman, A. Rephaeli, M. Entin-Meer, 2008, Clinical & Experimental Metastasis.

Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways

Z. Malik, A. Nudelman, A. Rephaeli, 2012, Investigational New Drugs.

Properties of a phosphoenolpyruvate: mannitol phosphotransferase system in Spirochaeta aurantia.

M. J. Newman, M. Saier, A. Rephaeli, 1977, The Journal of biological chemistry.

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.

D. Haas-Kogan, A. Nudelman, A. Rephaeli, 2007, Cancer letters.

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

S. Vandenberg, D. Haas-Kogan, A. Nudelman, 2005, Molecular Cancer Therapeutics.

An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells

A. Nudelman, S. Cutts, A. Rephaeli, 2022, Cancer Chemotherapy and Pharmacology.

Conformational transitions in fluorescein-labeled (Na,K)ATPase reconstituted into phospholipid vesicles.

D. Richards, A. Rephaeli, S. Karlish, 1986, The Journal of biological chemistry.

Proliferation‐associated changes of Ca2+ transport in myeloid leukemic cell lines

A. Rephaeli, Ester Rabizadeh, E. Rabizadeh, 1990, Journal of cellular physiology.

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units

Cesario Z. Cerna, D. V. Von Hoff, L. Siu, 2004, Investigational New Drugs.

Electrical potential accelerates the E1P(Na)----E2P conformational transition of (Na,K)-ATPase in reconstituted vesicles.

D. Richards, A. Rephaeli, S. Karlish, 1986, The Journal of biological chemistry.

Stimulation of Ca2+ uptake and protein phosphorylation in tumor cells by fibronectin.

E. Racker, M. Spector, A. Rephaeli, 1981, Journal of Biological Chemistry.

Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species

A. Nudelman, S. Cutts, A. Rephaeli, 2008, Cancer Chemotherapy and Pharmacology.

The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.

A. Nudelman, S. Cutts, A. Rephaeli, 2005, Journal of medicinal chemistry.

Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.

A. Nudelman, A. Rephaeli, Igor Makarovsky, 2008, Journal of medicinal chemistry.

Derivatives of butyric acid as potential anti‐neoplastic agents

A. Nudelman, A. Rephaeli, Ester Rabizadeh, 1991, International journal of cancer.

An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells.

Y. Honma, A. Rephaeli, T. Kasukabe, 1997, British Journal of Cancer.

Calmodulin stimulation of 45Ca2+ transport and protein phosphorylation in cholinergic synaptic vesicles.

A. Rephaeli, S. Parsons, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

A. Nudelman, S. Cutts, A. Rephaeli, 2006, Cancer research.

Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.

S. Sampson, A. Nudelman, A. Rephaeli, 2001, European journal of medicinal chemistry.

Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate

A. Nudelman, S. Cutts, A. Rephaeli, 2007, Molecular Cancer Therapeutics.

The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity

A. Nudelman, S. Cutts, A. Rephaeli, 2012, Investigational New Drugs.

Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.

A. Nudelman, A. Rephaeli, and Abraham Nudelman, 2000, Journal of medicinal chemistry.

Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines

A. Nudelman, S. Cutts, A. Rephaeli, 2006, Journal of Cancer Research and Clinical Oncology.

The Power and Potential of Doxorubicin‐DNA Adducts

A. Nudelman, S. Cutts, A. Rephaeli, 2005, IUBMB life.

Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer

A. Nudelman, A. Rephaeli, G. Kessler-Icekson, 2021, Pharmaceuticals.

Novel anticancer prodrugs of butyric acid. 2.

A. Nudelman, A. Rephaeli, E. Rabizadeh, 1992, Journal of medicinal chemistry.

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

A. Nudelman, S. Cutts, A. Rephaeli, 2003, Molecular cancer therapeutics.

Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors

A. Nudelman, A. Rephaeli, N. Tarasenko, 2018, Journal of cellular biochemistry.

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft

A. Nudelman, S. Cutts, A. Rephaeli, 2017, Investigational New Drugs.

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

Abraham Nudelman, Ada Rephaeli, S. Vandenberg, 2007, Neuro-oncology.

Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.

Abraham Nudelman, Ada Rephaeli, A. Nudelman, 2003, Molecular cancer therapeutics.

AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair

L. Moyal, Y. Ziv, A. Nudelman, 2018, Investigational New Drugs.

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin

L. Moyal, A. Nudelman, A. Rephaeli, 2016, PloS one.

The role of increased calcium influx rate in receptor mediated function of differentiating HL-60 cells.

A. Rephaeli, M. Shaklai, A. Aviram, 1990, Cell calcium.

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

A. Nudelman, S. Cutts, A. Rephaeli, 2012, Biochemical pharmacology.

Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).

A. Nudelman, S. Cutts, A. Rephaeli, 2001, Cancer research.

The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties.

Z. Malik, A. Nudelman, A. Rephaeli, 2007, Cancer letters.

In vivo efﬁcacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas 1

S. Vandenberg, D. Haas-Kogan, A. Nudelman, 2007 .

In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer

Z. Malik, A. Nudelman, S. Cutts, 2005, International journal of cancer.

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

A. Nudelman, S. Cutts, A. Rephaeli, 2010, Biochemical pharmacology.

The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model

D. Weinberger, A. Rephaeli, R. Sella, 2019, International journal of molecular sciences.

A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.

A. Nudelman, S. Cutts, A. Rephaeli, 2014, Biochemical pharmacology.

Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency.

J. Rishpon, Y. Shacham-Diamand, R. Margalit, 2008, Nanomedicine : nanotechnology, biology, and medicine.

Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells

A. Nudelman, A. Rephaeli, L. Maron, 2005, Journal of Cancer Research and Clinical Oncology.

Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

A. Nudelman, S. Cutts, A. Rephaeli, 2004, Oncology research.

Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis

A. Nudelman, A. Rephaeli, R. Zhuk, 2000, Journal of Cancer Research and Clinical Oncology.

Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9).

A. Nudelman, A. Rephaeli, L. Eisenbach, 1996, Israel journal of medical sciences.

Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug

A. Nudelman, A. Rephaeli, L. Eisenbach, 1993, FEBS letters.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts

A. Nudelman, S. Cutts, A. Rephaeli, 2013, Cancer Chemotherapy and Pharmacology.

Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.

Abraham Weizman, A. Nudelman, A. Rephaeli, 2009, Journal of medicinal chemistry.

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.

Abraham Weizman, A. Nudelman, A. Rephaeli, 2008, Journal of medicinal chemistry.

Abstracts of the 16th Annual Meeting of The Israel Society for Neuroscience Eilat, Israel, November 25–27, 2007

Yonina C. Eldar, Karl J. Friston, Leslie G. Ungerleider, 2008, Neural plasticity.

Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.

A. Nudelman, S. Cutts, A. Rephaeli, 2015, Current topics in medicinal chemistry.

Substrate specificity and kinetic characterization of sugar uptake and phosphorylation, catalyzed by the mannose enzyme II of the phosphotransferase system in Salmonella typhimurium.

M. Saier, A. Rephaeli, 1980, The Journal of biological chemistry.

Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy.

A. Nudelman, C. Chan, S. Cutts, 2009, Oncology research.

A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.

A. Nudelman, S. Cutts, A. Rephaeli, 2021, Biochemical pharmacology.

BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia

Abraham Weizman, A. Nudelman, A. Rephaeli, 2009, European Neuropsychopharmacology.

Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.

Z. Malik, A. Nudelman, A. Rephaeli, 2008, Journal of medicinal chemistry.

Abstracts of the 16th Annual Meeting of The Israel Society for Neuroscience Eilat, Israel, November 25–27, 2007

Yonina C. Eldar, Karl J. Friston, Leslie G. Ungerleider, 2008, Neural plasticity.

Early perceptual loss in depression

Yonina C. Eldar, Karl J. Friston, Charles R. Seger, 2007 .

Butyrate ( AN-9 ) with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl Molecular Basis for the Synergistic Interaction of Adriamycin Updated

A. Nudelman, S. Cutts, A. Rephaeli, 2001 .

Kinetic analyses of the sugar phosphate:sugar transphosphorylation reaction catalyzed by the glucose enzyme II complex of the bacterial phosphotransferase system.

M. Saier, A. Rephaeli, 1978, The Journal of biological chemistry.

Identification of Macromolecular Targets for Formaldehyde-Activated Adriamycin

Don R. Phillips, Abraham Nudelman, Ada Rephaeli, 2002 .

Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity dependent on photoactivation

Zvi Malik, G. Berkovitch, Abraham Nudelman, 2009, World Congress of the International Photodynamic Association.

Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006

Leslie G. Ungerleider, D. Amit, H. Seung, 2006, Neural Plasticity.

Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model.

I. Bahar, A. Nudelman, A. Rephaeli, 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies.

A. Nudelman, A. Rephaeli, A. Novogrodsky, 1994, International Journal of Oncology.

Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL‐60 leukemic cell line

A. Nudelman, A. Rephaeli, A. Aviram, 1994, International journal of cancer.

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.

Abraham Weizman, A. Nudelman, A. Rephaeli, 2008, Journal of medicinal chemistry.

New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

J. Collins, A. Nudelman, S. Cutts, 2010, Journal of medicinal chemistry.

Regulation of genes coding for enzyme constituents of the bacterial phosphotransferase system

M. Saier, A. Rephaeli, 1980, Journal of bacteriology.